Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2021-08-26 Notice of Dividend Amou…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
2021 INTERIM DIVIDEND
Notice of Dividend Amount Classification · 95% confidence The document is titled 'Interim Results Announcement For The Six Months Ended 30 June 2021' and contains detailed information about a semi-annual dividend declaration, including dividend amount, ex-dividend date, record date, payment date, and share registrar details. The document length is 3599 characters, which is relatively short and primarily focuses on dividend announcement details rather than comprehensive financial statements or analysis. There is no substantive financial data or management discussion present. The content aligns with a Notice of Dividend Amount filing rather than a full interim report or earnings release. Therefore, the document should be classified as a Notice of Dividend Amount (DIV).
2021-08-26 English
2021 INTERIM RESULTS ANNOUNCEMENT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 INTERIM RESULTS ANNOUNCEMENT' and contains detailed unaudited condensed consolidated financial statements for the six months ended 30 June 2021, including profit or loss, comprehensive income, financial position, segment information, and notes on accounting policies. It references HKAS 34 'Interim Financial Reporting' and includes comparative figures for the prior period. The length is substantial (15,000 characters), and the content includes actual financial data and analysis, not just an announcement or summary. Therefore, this document is a comprehensive interim financial report for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF KN026 IN CHINA
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding an exclusive license agreement with Jiangsu Alphamab for drug development and commercialization. It is a corporate announcement about a business deal, specifically a licensing agreement related to drug development. There are no financial statements, no regulatory certifications, no voting results, no management or board changes, and no earnings or annual report content. The document is not a report but an announcement of a corporate transaction. This fits best under Capital/Financing Update (CAP) as it relates to a significant business agreement impacting the company's development and commercialization activities, which often falls under financing or capital-related updates. The document length is short (3900 characters), and it is not a report publication announcement or regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2021-08-23 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2021
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the half year ended 30 June 2021. It includes detailed financial data such as revenue, net profit, cash flows, and changes in assets, prepared according to PRC Accounting Standards. The document is about a half-year period and contains substantive financial data and analysis, not just a brief summary or announcement. It is not a full annual report but a comprehensive interim financial report for a shorter period than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (9289 characters) and content confirm it is a full report, not just an announcement or certification. H1 2021
2021-08-19 English
VOLUNTARY ANNOUNCEMENT - STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT WITH FLAME BIOSCIENCES
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding a strategic partnership and license agreement with Flame Biosciences. It details the terms of the agreement, including upfront payments, milestone payments, and royalties, as well as background information on the drug candidates involved. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. The document is not a report publication announcement since it contains substantive content about the partnership rather than just announcing a report's availability. It is not related to board or management changes, voting results, or share transactions. The content fits best under Capital/Financing Update (CAP) as it involves a strategic partnership and licensing agreement with financial terms and implications for the company's capital and business development activities. The document length is 4627 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is CAP with high confidence.
2021-08-17 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited interim results for the six months ended 30 June 2021. It does not contain any financial data or the actual interim report itself, but merely announces the upcoming board meeting where such results will be approved. The document length is only 1266 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement related to an interim report but not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2021-08-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.